HIGHLIGHTS
- who: Yun-Tzu Lin and collaborators from the Centre Hospitalier Universitaire (CHU) de Saint-Eu0301tienne, France University, China have published the article: Case report: Heterogenous SMARCA4-deficient thoracic non-small cell lung carcinoma with various responses to nivolumab, in the Journal: (JOURNAL)
- how: The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
- future: The possible mechanism is that the defects in DNA repair result in cisplatin sensitivity in lung cancers with BRG1 knockdown so . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.